K50.1 K50.0 K50.8 K51.0 K51.2 K51.3 K51.8 Z94.4 K75.4
Conditions
Interventions
Group 1: vaccinations with MMR vaccine Priorix with documentation of side effects by questionaires and assessment of effectivity by increment of specific antibodies
Sponsors
Klinik für Kinder- und Jugendmedizin
Eligibility
Sex/Gender
All
Age
1 Years to 18 Years
Inclusion criteria
Inclusion criteria: As this is an observational study no inclusion criteria are defined. In principal, patients with chronic inflammatory bowel disease, autoimmune hepatitis and after liver transplantation being in steady state of there disease and having the indication of MMR vaccination due to insufficient protection against measles, mumps, and in female also rubella are included.
Exclusion criteria
Exclusion criteria: As this is an observational study no exclusion criteria are given for this study. Basically the recommendations from the enclosed leaflet have to be followed. In addition, we made some recommendations in our observational protocol. 1) We need a parent or patient consent to collect and analyze the data in this study. 2) If the patient is suspicious for an immunodeficiency this should be clarified first. 3) In addition to the leaflet we do not recommend immunization during an active underlying disease 4) Furthermore, we specified some conditions that may affect safety and efficiency, which should be avoided. In detail these conditions are stated in the observational procotol.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Safety of MMR vaccination using the immunological check list after 12-16 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| Effectivity of vaccination with increment of vaccine specific antibody formation after 12-16 weeks | — |
Countries
Germany
Contacts
Public ContactCarsten Posovszky
Klinik für Kinder- und Jugendmedizin
Outcome results
None listed